

Buy Eloralintide Canada | Amylin Agonist
Janoshik
Batch ELOR-CA-26G-10
Buy Eloralintide Canada | Amylin Agonist
Selective Amylin Receptor Agonist
Also known as Elaronitide, Elorantide, LY3841136
This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
Note that no compound named "elaronitide" appears in PubMed, PubChem, or the INN register. The vial artwork spelling appears to be in error.
Third-party tested for purity, ID, quantity.
Eloralintide is a selective agonist of the AMY1 amylin receptor, engineered with a fatty-diacid conjugate that supports albumin binding and an extended half-life. Research has characterized its selectivity for AMY1R over the calcitonin receptor and other amylin receptor subtypes.
Clinical research has evaluated the compound across phase 1 and phase 2 programmes, examining amylin-pathway pharmacology and body-weight endpoints under controlled conditions.
Eloralintide was developed as part of research into amylin-pathway agonists as an alternative to incretin-based mechanisms for metabolic regulation. Discovery and early characterization work described its receptor selectivity and long-acting design.
Subsequent phase 1 and phase 2 studies characterized its pharmacological profile in obesity research populations.
Research into eloralintide focuses on selective amylin receptor activation and its metabolic consequences. Frameworks evaluate receptor-subtype selectivity, pharmacokinetics of the long-acting design, and body-weight endpoints under controlled clinical conditions.
3 of the 4 areas below are addressed directly by a paper cited on this page.
Amylin (AMY1R) receptor selectivity models
Addressed on this page by Briere 2025, Billings 2025, Bhattachar 2026. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Briere, DA. et al. (2025) — Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
- Billings, LK. et al. (2025) — Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
- Bhattachar, S. et al. (2026) — Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept
Long-acting peptide pharmacokinetics
Addressed on this page by Bailey 2026, Bhattachar 2026. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Bailey, CJ. et al. (2026) — Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes
- Bhattachar, S. et al. (2026) — Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept
Metabolic and body-weight endpoint research
No paper cited on this page reports on metabolic, body or weight. This heading marks where Eloralintide is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Comparative incretin and amylin pathway studies
Addressed on this page by Briere 2025, Billings 2025, Bhattachar 2026. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Briere, DA. et al. (2025) — Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
- Billings, LK. et al. (2025) — Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
- Bhattachar, S. et al. (2026) — Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept
The references section of this page cites 4 primary papers published between 2025 and 2026 — a limited but non-trivial record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Eloralintide is frequently listed as a peptide by suppliers in this market. It is not one. The structure published on this page is the compound's actual chemistry, and research on it should be read against its own class rather than against peptide literature.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Eloralintide, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Eloralintide is also referred to as elora, LY3841136, and technically as Elaronitide, Elorantide, LY3841136.
Eloralintide is commonly described online in connection with weight loss, appetite suppression and fat reduction. In the research literature the same compound is filed under amylin (AMY1R) receptor selectivity models, long-acting peptide pharmacokinetics and metabolic and body-weight endpoint research.
Of the 4 papers cited on this page, published between 2025 and 2026, 2 report work in human participants — Billings 2025 and Bhattachar 2026. Human data for a molecule is not the same as evidence for material supplied as a research compound: published trials use pharmaceutical-grade product under medical supervision at defined doses. What is established for the material sold here is its measured purity and content per lot.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for Eloralintide is per lot, not per product. The current 10mg lot ELOR-CA-26G-10 returned 99.81% purity, 12.42 mg measured, 124.2% of the labelled 10 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
Purity is half the number. It states what fraction of the material in the vial is Eloralintide; it says nothing about how much material is in the vial, and a short-filled vial can return a purity result that is entirely accurate. The figure that answers the second question is measured mass against expected content — for Eloralintide, this lot measured 124.2% of its labelled 10 mg. Both numbers are published for every lot, whichever way they fall.
The lot code printed on the vial matches the code on the certificate for Eloralintide. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy Eloralintide in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
- Lyophilized storage
- −20 °C long-term; stable at room temperature in transit
- After reconstitution
- 2–8 °C
- Light
- Protect from UV and direct light
- Freeze-thaw
- Avoid repeated cycles
- Vehicle
- Solvent selection depends on the compound; consult the published literature
- Format
- Lyophilized powder
Eloralintide is supplied as lyophilized powder. It is not a peptide, and solvent behaviour follows from its own chemistry rather than from the aqueous-vehicle conventions that apply to peptide material — the published literature for this compound is the reference for solvent selection, not a general peptide protocol.
Dry storage below freezing and protection from light are the general controls. As with any lyophilized material, the powder frequently sits as a thin film at the base of the vial and is easy to mistake for an empty vial before inspection.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
- 1 × sealed glass vial (10mg / Single Vial), batch-labelled
- The batch-linked Certificate of Analysis for the exact lot shipped
- Discreet outer packaging with no product names on the exterior
- Canada Post Xpress, tracked, typically 1–2 business days from Alberta
- Bacteriostatic water or any other reconstitution vehicle
- Syringes, needles or filters
- Dosing, administration or protocol guidance of any kind
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of eloralintide. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
PubMedEloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
PubMedEloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept
PubMedLong-acting amylin-related peptides as therapies for obesity and type 2 diabetes
PubMedRelated
You May Also Like

Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
$60.00
$70.00
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
$35.00
$40.00
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$70.00

Pentadecapeptide studied for angiogenesis signaling, tissue repair pathways, and cellular regeneration research
$50.00
$60.00